EAU Guidelines on Erectile Dysfunction: An Update

European Urology

Volumn 49, Issue 5, 2006, Pages 806-815

  Wespes, Eric ^a   Amar, Edouard ^b   Hatzichristou, Dimitrios ^c   Hatzimouratidis, Kosta ^c   Montorsi, Francesco ^d   Pryor, John ^e   Vardi, Yoram ^f  

^a ERASME HOSPITAL   (Belgium)

^b BICHAT HOSPITAL   (France)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d Divisione di Medicina II   (Italy)

^e LISTER HOSPITAL   (United Kingdom)

^f RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Diagnosis and treatment; EAU guidelines; Erectile dysfunction; Impotence

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMYL NITRATE; AMYL NITRITE; ANTIHYPERTENSIVE AGENT; APOMORPHINE; GLUCOSE; GLYCERYL TRINITRATE; ISOSORBIDE DINITRATE; ISOSORBIDE MONONITRATE; LIPID; MINOXIDIL; ORGANIC NITRATE; PAPAVERINE; PHOSPHODIESTERASE V INHIBITOR; PROSTAGLANDIN E1; SILDENAFIL; TADALAFIL; TESTOSTERONE; VARDENAFIL; VASOACTIVE AGENT;

ABNORMAL VISION; ANAMNESIS; ANGINA PECTORIS; ARTICLE; ATHEROSCLEROSIS; BACKACHE; BURNING SENSATION; CARDIOTOXICITY; CARDIOVASCULAR SYSTEM; CAVERNOSOGRAPHY; CLINICAL PRACTICE; CORPUS CAVERNOSUM; DEVICE; DIABETES MELLITUS; DIAGNOSTIC TEST; DIZZINESS; DOSE RESPONSE; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ENDOCRINOLOGY; EPIDEMIOLOGICAL DATA; ERECTILE DYSFUNCTION; ERYTHEMA; GLUCOSE ASSAY; HEALTH BEHAVIOR; HEMODYNAMICS; HORMONE DEFICIENCY; HOT FLUSH; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOGONADISM; HYPOTENSION; INCIDENCE; ISCHEMIC OPTIC NEUROPATHY; LABORATORY TEST; LIFESTYLE; LIPID ANALYSIS; MYALGIA; NEUROLOGIC DISEASE; NOSE CONGESTION; PAIN; PATIENT SATISFACTION; PELVIS SURGERY; PENILE FIBROSIS; PENIS DISEASE; PENIS ERECTION; PENIS GLANS; PENIS PROSTHESIS; PEYRONIE DISEASE; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PRIAPISM; PRIORITY JOURNAL; PROSTATE DISEASE; PROSTATE HYPERTROPHY; PSYCHIATRIC DIAGNOSIS; QUESTIONNAIRE; RECTUM SURGERY; REVASCULARIZATION; RISK FACTOR; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTION; SMOKING; TESTOSTERONE DEFICIENCY; URETHRA DISEASE; UROLOGIC SURGERY; VACUUM CONSTRICTION DEVICE; VALIDATION PROCESS;

EUROPE; HUMANS; IMPOTENCE; MALE; SOCIETIES, MEDICAL; UROLOGY;

EID: 33645794792     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2006.01.028     Document Type: Article

References (45)

1. Wespes E., Amar E., Hatzichristou D.G., Montorsi F., Pryor J., and Vardi Y. Guidelines on erectile dysfunction. Eur Urol 41 (2002) 1-5
2. Kubin M., Wagner G., and Fugi-Meyer A.R. Epidemiology and erectile dysfunction. Int J Impot Res 15 (2003) 63-71
3. Lue T.F. Erectile dysfunction. N Engl J Med 342 (2000) 1802-1813
4. Roumeguere T., Wespes E., Carpentier Y., Hoffmann P., and Schulman C.C. Erectile dysfunction is associated with a high prevalence of hyperlipidemia and coronary heart disease risk. Eur Urol 44 (2003) 355-359
5. Derby C.A., Mohr B.A., Goldstein I., Feldman H.A., Johannes C.B., and McKinlay J.B. Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk?. Urology 56 (2000) 302-306
6. Esposito K., Giugliano F., Di Palo C., et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA 291 (2004) 2978-2984
7. Hatzichristou D., Hatzimouratidis K., Bekas M., Apostolidis A., Tzortzis V., and Yannakoyorgos K. Diagnostic steps in the evaluation of patients with erectile dysfunction. J Urol 168 (2002) 615-620
8. Rosen R., Altwein J., Boyle P., et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 44 (2003) 637-649
9. Davis-Joseph B., Tiefer L., and Melman A. Accuracy of the initial history and physical examination to establish the etiology of erectile dysfunction. Urology 45 (1995) 498-502
10. Rosen R.C., Riley A., Wagner G., Osterloh I.H., Kirkpatrick J., and Mishra A. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 49 (1997) 822-830
11. Lue T.F., Giuliano F., Montorsi F., et al. Summary of the Recommendations on Sexual Dysfunctions in Men. J Sex Med 1 (2004) 6-23
12. Kostis J.B., Jackson G., Rosen R., et al. Sexual dysfunction and cardiac risk. Am J Cardiol 96 (2005) 313-321
13. Montorsi F., Briganti A., Salonia A., et al. Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol 44 (2003) 360-365
14. DeBusk R., Drory Y., Goldstein I., et al. Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton Consensus Panel. Am J Cardiol 86 (2000) 62F-68F
15. Hatzichristou D.G., Hatzimouratidis K., Ioannides E., Yannakoyorgos K., Dimitriadis G., and Kalinderis A. Nocturnal penile tumescence and rigidity monitoring in young potent volunteers: reproducibility, evaluation criteria and the effect of sexual intercourse. J Urol 159 (1998) 1921-1926
16. Hatzichristou D.G., Hatzimouratidis K., Apostolidis A., Ioannidis E., Yannakoyorgos K., and Kalinderis A. Hemodynamic characterization of a functional erection. Arterial and corporeal veno-occlusive function in patients with a positive intracavernosal injection test. Eur Urol 36 (1999) 60-67
17. Meuleman E.J., and Diemont W.L. Investigation of erectile dysfunction. Diagnostic testing for vascular factors in erectile dysfunction. Urol Clin North Am 22 (1995) 803-819
18. Hatzichristou D., Rosen R.C., Broderick G., et al. Clinical evaluation and management strategy for sexual dysfunction in men and women. J Sex Med 1 (2004) 49-57
19. Moyad M.A., Barada J.H., Lue T.F., Mulhall J.P., Goldstein I., and Fawzy A. Prevention and treatment of erectile dysfunction using lifestyle changes and dietary supplements: what works and what is worthless, part I. Urol Clin North Am 31 (2004) 249-257
20. Moyad M.A., Barada J.H., Lue T.F., Mulhall J.P., Goldstein I., and Fawzy A. Prevention and treatment of erectile dysfunction using lifestyle changes and dietary supplements: what works and what is worthless, part II. Urol Clin North Am 31 (2004) 259-273
21. Morales A., and Heaton J.P. Hormonal erectile dysfunction. Evaluation and management. Urol Clin North Am 28 (2001) 279-288
22. Rao D.S., and Donatucci C.F. Vasculogenic impotence. Arterial and venous surgery. Urol Clin North Am 28 (2001) 309-319
23. Wespes E., Wildschutz T., Roumeguere T., and Schulman C.C. The place of surgery for vascular impotence in the third millennium. J Urol 170 (2003) 1284-1286
24. Rosen R.C. Psychogenic erectile dysfunction. Classification and management. Urol Clin North Am 28 (2001) 269-278
25. Goldstein I., Lue T.F., Padma-Nathan H., Rosen R.C., Steers W.D., and Wicker P.A. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998;338:1397-404. Erratum. N Engl J Med 339 (1998) 59
26. Moncada I., Jara J., Subira D., Castano I., and Hernandez C. Efficacy of sildenafil citrate at 12 hours after dosing: re-exploring the therapeutic window. Eur Urol 46 (2004) 357-360 discussion 60-1
27. Brock G.B., McMahon C.G., Chen K.K., et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 168 (2002) 1332-1336
28. Porst H., Padma-Nathan H., Giuliano F., Anglin G., Varanese L., and Rosen R. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology 62 (2003) 121-125 discussion 5-6
29. Montorsi F., Verheyden B., Meuleman E., et al. Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction. Eur Urol 45 (2004) 339-344 discussion 44-5
30. Hellstrom W.J., Gittelman M., Karlin G., et al. Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology 61 (2003) 8-14
31. Bischoff E., and Schneider K. A conscious-rabbit model to study vardenafil hydrochloride and other agents that influence penile erection. Int J Impot Res 13 (2001) 230-235
32. Potempa A.J., Ulbrich E., Bernard I., and Beneke M. Efficacy of vardenafil in men with erectile dysfunction: a flexible-dose community practice study. Eur Urol 46 (2004) 73-79
33. Kloner R.A. Novel phosphodiesterase type 5 inhibitors: assessing hemodynamic effects and safety parameters. Clin Cardiol 27 (2004) I20-I25
34. Hatzichristou D.G. Phosphodiesterase 5 inhibitors and nonarteritic anterior ischemic optic neuropathy (NAION): coincidence or causality?. J Sex Med 2 (2005) 751-758
35. Buono L.M., Foroozan R., Sergott R.C., and Savino P.J. Nonarteritic anterior ischemic optic neuropathy. Curr Opin Ophthalmol 13 (2002) 357-361
36. Hayreh S.S., Joos K.M., Podhajsky P.A., et al. Systemic diseases associated with nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 118 (1994) 766-780
37. Aversa A., Isidori A., Spera G., Lenzi A., and Fabri A. Androgens improves cavernous dilatation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol 58 (2003) 632-638
38. Behr-Roussel D., Gorny D., Mevel K., et al. Chronic sildenafil improves erectile function and endothelium-dependent cavernosal relaxations in rats: lack of tachyphylaxis. Eur Urol 47 (2005) 87-91
39. Dula E., Bukofzer S., Perdok R., and George M. Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction. Eur Urol 39 (2001) 558-563 discussion: 564
40. Eardley I., Wright P., MacDonagh R., Hole J., and Edwards A. An open-label, randomized, flexible-dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine hydrochloride in men with erectile dysfunction. BJU Int 93 (2004) 1271-1275
41. Goldstein I., Payton T.R., and Schechter P.J. A double-blind, placebo-controlled, efficacy and safety study of topical gel formulation of 1% alprostadil (Topiglan) for the in-office treatment of erectile dysfunction. Urology 57 (2001) 301-305
42. Lewis R.W., and Witherington R. External vacuum therapy for erectile dysfunction: use and results. World J Urol 15 (1997) 78-82
43. Linet O.I., and Ogrinc F.G. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. N Engl J Med 334 (1996) 873-877
44. Padma-Nathan H., Hellstron W.J.G., et al. Treatment of men with erectile dysfunction with transurethral alprostadil. N Engl J Med 336 (1997) 1-7
45. Montague D.K., and Angermeier K.W. Penile prosthesis implantation. Urol Clin North Am 28 (2001) 355-361